Development of JFH1-based cell culture systems for hepatitis C virus genotype 4a and evidence for cross-genotype neutralization
about
Signal peptidase complex subunit 1 participates in the assembly of hepatitis C virus through an interaction with E2 and NS2Resistance of Hepatitis C Virus to Inhibitors: Complexity and Clinical ImplicationsProduction of Infectious Genotype 1b Virus Particles in Cell Culture and Impairment by Replication Enhancing MutationsHepatitis C virus replicons: dinosaurs still in business?Hepatitis C Virus NS2 Protein Contributes to Virus Particle Assembly via Opposing Epistatic Interactions with the E1-E2 Glycoprotein and NS3-NS4A Enzyme ComplexesDevelopment of NS3/4A Protease-Based Reporter Assay Suitable for Efficiently Assessing Hepatitis C Virus InfectionStructural and Functional Studies of Nonstructural Protein 2 of the Hepatitis C Virus Reveal Its Key Role as Organizer of Virion AssemblyPersistent growth of a human plasma-derived hepatitis C virus genotype 1b isolate in cell cultureHigh-throughput screening and rapid inhibitor triage using an infectious chimeric Hepatitis C virusHuman monoclonal antibodies to a novel cluster of conformational epitopes on HCV E2 with resistance to neutralization escape in a genotype 2a isolateA Hepatitis C Virus Envelope Polymorphism Confers Resistance to Neutralization by Polyclonal Sera and Broadly Neutralizing Monoclonal AntibodiesBroadly neutralizing antibodies with few somatic mutations and hepatitis C virus clearanceDevelopment of an intergenotypic hepatitis C virus (HCV) cell culture method to assess antiviral susceptibilities and resistance development of HCV NS3 protease genes from HCV genotypes 1 to 6Novel infectious cDNA clones of hepatitis C virus genotype 3a (strain S52) and 4a (strain ED43): genetic analyses and in vivo pathogenesis studiesChallenge pools of hepatitis C virus genotypes 1-6 prototype strains: replication fitness and pathogenicity in chimpanzees and human liver-chimeric mouse models.Human broadly neutralizing antibodies to the envelope glycoprotein complex of hepatitis C virusHepatitis C virus experimental model systems and antiviral drug research.Analysis of functional differences between hepatitis C virus NS5A of genotypes 1-7 in infectious cell culture systems.Colorimetric focus-forming assay with automated focus counting by image analysis for quantification of infectious hepatitis C virionsA Gaussia luciferase cell-based system to assess the infection of cell culture- and serum-derived hepatitis C virus.Potential treatment options and future research to increase hepatitis C virus treatment response rateIsolation of human monoclonal antibodies to the envelope e2 protein of hepatitis C virus and their characterization.Productive homologous and non-homologous recombination of hepatitis C virus in cell culture.Neutralizing antibodies in patients with chronic hepatitis C, genotype 1, against a panel of genotype 1 culture viruses: lack of correlation to treatment outcome.MicroRNA-122 antagonism against hepatitis C virus genotypes 1-6 and reduced efficacy by host RNA insertion or mutations in the HCV 5' UTR.Hypervariable region 1 differentially impacts viability of hepatitis C virus strains of genotypes 1 to 6 and impairs virus neutralizationEfficient culture adaptation of hepatitis C virus recombinants with genotype-specific core-NS2 by using previously identified mutations.In vivo evaluation of the cross-genotype neutralizing activity of polyclonal antibodies against hepatitis C virus.Permissivity of primary human hepatocytes and different hepatoma cell lines to cell culture adapted hepatitis C virus.Naturally selected hepatitis C virus polymorphisms confer broad neutralizing antibody resistance.Griffithsin has antiviral activity against hepatitis C virusNeutralization resistance of hepatitis C virus can be overcome by recombinant human monoclonal antibodiesProduction and characterization of high-titer serum-free cell culture grown hepatitis C virus particles of genotype 1-6.Breadth of neutralization and synergy of clinically relevant human monoclonal antibodies against HCV genotypes 1a, 1b, 2a, 2b, 2c, and 3a.Production of infectious chimeric hepatitis C virus genotype 2b harboring minimal regions of JFH-1.Adaptive Mutations Enhance Assembly and Cell-to-Cell Transmission of a High-Titer Hepatitis C Virus Genotype 5a Core-NS2 JFH1-Based Recombinant.Immunoglobulin with High-Titer In Vitro Cross-Neutralizing Hepatitis C Virus Antibodies Passively Protects Chimpanzees from Homologous, but Not Heterologous, ChallengeRobust full-length hepatitis C virus genotype 2a and 2b infectious cultures using mutations identified by a systematic approach applicable to patient strains.Hepatitis C Virus E1 and E2 Proteins Used as Separate Immunogens Induce Neutralizing Antibodies with Additive PropertiesApplying antibody-sensitive hypervariable region 1-deleted hepatitis C virus to the study of escape pathways of neutralizing human monoclonal antibody AR5A.
P2860
Q24322876-84C9062D-7FE8-4548-9D51-867113C47901Q26777408-B7E78B18-FF9A-4369-B3B3-7D182B935050Q27488616-09F2F7E5-CFD1-4A2E-8F8C-76EF91A908F8Q27488905-1DCC1E74-9D79-48E1-A309-CD0B9D279528Q27489514-B538DE66-1C8A-46CF-94DD-F8A98BE01BFDQ27490296-F7D8F920-BDFD-4FA4-B215-BB18AE2F0052Q27666400-66DBB1B0-9702-4B34-A4D1-F502E777829CQ28473992-E5540D4F-5143-4CDA-A133-1BDA5330F94BQ28482091-13A014CA-85C4-41C9-BC60-B24F3B555E20Q28482261-79AC2009-9318-40BA-9759-3690862380F3Q30383939-A476531D-55A5-4048-A72D-E05E56138C8DQ33631104-FD7AFEB7-2D2D-47D1-A988-1EB223115DDEQ33826766-1100BF0C-29A4-4C49-A3D7-E43423380899Q33826844-812BEAE4-CA19-44FF-8715-5EA83E214AD9Q34140014-8E3CA960-2F1B-4179-9FDF-61EB21262EC5Q34228030-160447FC-4A41-47B4-9BCC-904F1EA45D24Q34235286-D5BB80A0-6B34-4FF9-9365-5D1E24E13304Q34288777-AD87CF05-F3F8-4DB4-BF1F-F48529A9939FQ34399607-7FF38886-BE94-4FE2-B28F-D2D8A0577DCFQ34541812-ED710814-DFAC-4A44-9A8B-9BCA9073E158Q34576190-8BC1B70B-D76C-4F7E-B45B-D31660C9C82BQ34586396-79684CC1-3D24-4FF2-BA98-42663AFD131CQ34649619-A5FB93B7-9112-4B9A-9BA0-5980FB4D4C46Q34717544-547722BB-4CCA-4E24-877C-9F968BD269CCQ34721015-1A93926B-6504-4560-977B-657E7A1AF561Q34741652-5C4BB84F-40E7-4422-B9F7-73C270749D27Q34742954-23FCF4C5-ED53-4F8F-89C7-90BB86471FB7Q34816677-1DB4D536-AF68-4E49-BC99-129834EA0828Q34936072-656FB2F4-E383-43F0-882C-1A7D57590DCEQ35242585-68D0E3C7-4CCF-4A4D-9C71-834AD5D8730AQ35363633-9ACC7082-7911-4F53-BA41-5E7CDEF8C152Q35557495-5BA7353C-1F6E-4D63-A05D-20D04FB929F8Q35557533-20D9BBD1-7AF1-41B0-8398-53938D8D4813Q35557994-3AC8FC7F-E72C-4756-B143-089C34956D14Q35826594-08AAE6A6-11AC-4353-8BE5-524B2BB33419Q35861270-A3FAE08C-016F-424E-8703-F4944AA7A19AQ35913863-25871C70-3FB1-4B3C-B83B-B9C4ABE1A500Q35935502-C08A63C5-B9DF-4953-86E0-CD2846580337Q35953659-F52DE2E5-6305-42A0-94E4-8D44D3B6241EQ36288404-6C111AC6-F9F6-456B-A1E4-F10751C84FE6
P2860
Development of JFH1-based cell culture systems for hepatitis C virus genotype 4a and evidence for cross-genotype neutralization
description
2008 nî lūn-bûn
@nan
2008 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
name
Development of JFH1-based cell ...... cross-genotype neutralization
@ast
Development of JFH1-based cell ...... cross-genotype neutralization
@en
Development of JFH1-based cell ...... cross-genotype neutralization
@nl
type
label
Development of JFH1-based cell ...... cross-genotype neutralization
@ast
Development of JFH1-based cell ...... cross-genotype neutralization
@en
Development of JFH1-based cell ...... cross-genotype neutralization
@nl
prefLabel
Development of JFH1-based cell ...... cross-genotype neutralization
@ast
Development of JFH1-based cell ...... cross-genotype neutralization
@en
Development of JFH1-based cell ...... cross-genotype neutralization
@nl
P2093
P2860
P50
P356
P1476
Development of JFH1-based cell ...... cross-genotype neutralization
@en
P2093
Anne M Hoegh
Harvey J Alter
Tanja B Jensen
Troels K H Scheel
P2860
P304
P356
10.1073/PNAS.0711044105
P407
P577
2008-01-22T00:00:00Z